Do Vytrus Biotech's (BME:VYT) Earnings Warrant Your Attention?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away.

Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like Vytrus Biotech (BME:VYT). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Vytrus Biotech with the means to add long-term value to shareholders.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Vytrus Biotech's Improving Profits

In the last three years Vytrus Biotech's earnings per share took off; so much so that it's a bit disingenuous to use these figures to try and deduce long term estimates. Thus, it makes sense to focus on more recent growth rates, instead. In impressive fashion, Vytrus Biotech's EPS grew from €0.14 to €0.39, over the previous 12 months. It's not often a company can achieve year-on-year growth of 184%. The best case scenario? That the business has hit a true inflection point.

Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. Vytrus Biotech shareholders can take confidence from the fact that EBIT margins are up from 16% to 33%, and revenue is growing. Ticking those two boxes is a good sign of growth, in our book.

You can take a look at the company's revenue and earnings growth trend, in the chart below. For finer detail, click on the image.

View our latest analysis for Vytrus Biotech

Vytrus Biotech isn't a huge company, given its market capitalisation of €107m. That makes it extra important to check on its balance sheet strength.

Are Vytrus Biotech Insiders Aligned With All Shareholders?

It's pleasing to see company leaders with putting their money on the line, so to speak, because it increases alignment of incentives between the people running the business, and its true owners. So it is good to see that Vytrus Biotech insiders have a significant amount of capital invested in the stock. As a matter of fact, their holding is valued at €36m. This considerable investment should help drive long-term value in the business. That amounts to 34% of the company, demonstrating a degree of high-level alignment with shareholders.

Should You Add Vytrus Biotech To Your Watchlist?

Vytrus Biotech's earnings have taken off in quite an impressive fashion. That EPS growth certainly is attention grabbing, and the large insider ownership only serves to further stoke our interest. At times fast EPS growth is a sign the business has reached an inflection point, so there's a potential opportunity to be had here. So at the surface level, Vytrus Biotech is worth putting on your watchlist; after all, shareholders do well when the market underestimates fast growing companies. You should always think about risks though. Case in point, we've spotted 3 warning signs for Vytrus Biotech you should be aware of, and 1 of them can't be ignored.

While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in ES with promising growth potential and insider confidence.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.